Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

The gastrointestinal tract plays a role in the development and treatment of metabolic
diseases. During a meal, the gut provides crucial information to the brain regarding …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Abstract Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment option
for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the …

Context Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater …

Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose homeostasis, reduce
bodyweight, and over time benefit cardiovascular health in type 2 diabetes mellitus (T2DM) …

Uncertainty exists as to whether the glucose-dependent insulinotropic polypeptide receptor
(GIPR) should be activated or inhibited for the treatment of obesity. Gipr was recently …

The discovery and development of so-called gut hormone co-agonists as a new class of
drugs for the treatment of diabetes and obesity is considered a transformative breakthrough …